Health Behavior Clinical Trial
— SomaSignalOfficial title:
Evaluating the Impact of SomaSignal Tests on Medical Management and Change in Risk in Patients at Higher Risk of Cardiovascular Disease: A Feasibility and an Adaptive Implementation Study (SomaSignal Study)
Feasibility Study Informed consent will be obtained using an IRB-approved form. The first 12 consenting patients will be placed in the planned assessment group for feasibility and will not be randomized. These participants will undergo visits and blood draw collection at 3 months. They will be informed of their SomaSignal Test results at baseline and 3 months. Recommendations for any medical management changes will be made based on an understanding of those results. Randomized Study The succeeding 200 participants will be randomized using permuted mixed block randomization, in a 2:1 ratio, i.e., 2 participants to Group 1 (informed of their test results) and 1 participant to Group 2 (uninformed of their test results). At enrollment, and for 6 months thereafter, clinical information will be obtained from each participant's medical records, and/or directly from the participant during procedures, treatments, study-specific visits, and/or follow-up visits. Data collected for the study will have data linkage at SomaLogic, Inc., where data analysis will be done. At baseline and 6-months (+30 days) post-enrollment, patients will undergo a patient visit and blood collection. Blood will be collected as a stand-alone sample collection, or when other ordered lab work is done, or from access lines inserted during a usual or specialized care. Samples will be sent to the Intermountain Central laboratory for clinical testing. A sample will also be processed and shipped to SomaLogic, Inc. for analysis at baseline and 6 months. For the informed arm, the SomaSignal Test reports will be provided at the time they are available (2 to 4 weeks after the blood draw). Any recommended changes in medical management will be recorded in the case report forms and will be verified by the Principal Investigator. For the uninformed arm, the SomaSignal Test results will not be provided to the study team until after the 6-month post-test visit. Adjustments, if any, would be made to the participant's management at that time.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | August 12, 2024 |
Est. primary completion date | August 12, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Male or female 40 - 80 years of age 2. Receiving care at Intermountain Medical Center 3. At higher than typical risk for cardiovascular events, as assessed by the Principal Investigator or his/her delegate (further defined in the protocol) 4. Currently not pregnant 5. Ability to understand and sign a written informed consent form which must be obtained prior to initiation of any study procedures 6. Willing and able to comply with any virtual or in-person follow-up visits, tests, and schedule of evaluations 7. Willing and able to undergo a blood draw for SomaSignal Tests 8. Willing and able to provide access to their electronic health records Exclusion Criteria: 1. Presence of Systemic Lupus Erythematosus 2. Inability to communicate appropriately 3. Participation in any other clinical trials involving investigational or marketed products within 30 days prior to entry in the study 4. Other conditions that in the opinion of the Principal Investigator and/or Co-Principal Investigators may increase risk to the participants and/or compromise the quality of the clinical trial 5. The Principal Investigator and/or Co-Principal Investigator determine(s) that the participant is not eligible for participation in this research study. |
Country | Name | City | State |
---|---|---|---|
United States | Intermountain Medical Center | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
Intermountain Health Care, Inc. | SomaLogic, Inc. |
United States,
Ganz P, Heidecker B, Hveem K, Jonasson C, Kato S, Segal MR, Sterling DG, Williams SA. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. JAMA. 2016 Jun 21;315(23):2532-41. doi: 10.1001/jama.2016.5951. — View Citation
Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, Jonasson C, Sarzynski MA, Shipley MJ, Alexander L, Ash J, Bauer T, Chadwick J, Datta G, DeLisle RK, Hagar Y, Hinterberg M, Ostroff R, Weiss S, Ganz P, Wareham NJ. Plasma protein patterns as comprehensive indicators of health. Nat Med. 2019 Dec;25(12):1851-1857. doi: 10.1038/s41591-019-0665-2. Epub 2019 Dec 2. — View Citation
Williams SA, Murthy AC, DeLisle RK, Hyde C, Malarstig A, Ostroff R, Weiss SJ, Segal MR, Ganz P. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib. Circulation. 2018 Mar 6;137(10):999-1010. doi: 10.1161/CIRCULATIONAHA.117.028213. Epub 2017 Oct 3. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Porportion of participants that undergo a change in their treatment plan after receipt of the SomaSignal test. | Lifestyle changes are defined as referrals for A structured dietary or weight loss program (ie., Intermountain's Weigh to Health) Physical therapy for cardiovascular fitness Cardiac rehabilitation Medications Antianginals Antiarrhythmics Antilipidemics Coagulation modifiers Heart failure medications Hypertension medications Antidiabetic Antiplatelets Patients will receive a point for each change made. Documentation will be made on whether the change was made because of the SomaSignal results, a side-effect or a request by the patient, or a non-SomaSignal test related reason. The total number of changes at baseline and 6-months will be computed for each patient and will be compared between the arms. |
Baseline, 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Recruiting |
NCT04356924 -
Psychological Treatment to Support the Consequences of Cognitive Impairment
|
N/A | |
Completed |
NCT05509049 -
Precision Nudging Drives Wellness Visit Attendance at Scale
|
N/A | |
Completed |
NCT03904992 -
Intervention With a Progressive Web App for the Promotion of Healthy Habits in Preschoolers
|
N/A | |
Completed |
NCT05509270 -
Efficacy of Communication Modalities for Promoting Flu Shots
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Completed |
NCT03081520 -
Affective Responses Following Aerobic Exercise With Different Intensities
|
N/A | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03982095 -
Survey on Lifestyle, Perceived Barriers and Development of Change in Patients With Prostate Cancer
|
||
Completed |
NCT02996864 -
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
|
N/A | |
Completed |
NCT02777086 -
Sustainable HIV Risk Reduction Strategies for Probationers
|
N/A | |
Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
Active, not recruiting |
NCT04152824 -
Readiness Supportive Leadership Training
|
N/A | |
Recruiting |
NCT05541653 -
The IGNITE Study on Concentrated Investment in Black Neighborhoods
|
N/A | |
Completed |
NCT03875768 -
Nourish: A Digital Health Program to Promote the DASH Eating Plan Among Adults With High Blood Pressure
|
N/A | |
Completed |
NCT04089020 -
Walking to School Supports
|
N/A | |
Completed |
NCT03646903 -
Reducing Help-Seeking Stigma in Young Adults at Elevated Suicide Risk
|
N/A | |
Completed |
NCT03548077 -
POWERPLAY: Promoting Men's Health at Work
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Completed |
NCT06365450 -
Breast and Cervical Cancer Education Program
|
N/A |